A better buy-in window may exist right now for Akebia Therapeutics Inc. (AKBA)

With 14.01 million shares changed hands, the volume of the stock remained heavier than its average volume of 4.16 million shares. The 52-week range on AKBA shows that it touched its highest point at $2.48 and its lowest point at $0.49 during that stretch. It currently has a 1-year price target of $5.00. Beta for the stock currently stands at 0.79.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AKBA was down-trending over the past week, with a drop of -24.88%, but this was up by 3.16% over a month. Three-month performance surged to 27.34% while six-month performance rose 45.54%. The stock gained 169.42% in the past year, while it has gained 31.45% so far this year. A look at the trailing 12-month EPS for AKBA yields -0.28 with Next year EPS estimates of -0.27. For the next quarter, that number is -0.07. This implies an EPS growth rate of 0.32% for this year and 1.92% for next year.

Float and Shares Shorts:

At present, 194.58 million AKBA shares are outstanding with a float of 184.15 million shares on hand for trading. On Mar 15, 2024, short shares totaled 10.13 million, which was 4.84% higher than short shares on Feb 15, 2024. In addition to AKBA as the firm’s Akebia Therapeutics, Inc., AMBA serves as its Ambarella, Inc.

Institutional Ownership:

Through their ownership of 26.28% of AKBA’s outstanding shares, institutional investors have minority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AKBA since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.

Dividends & Yield:

In terms of dividends, AKBA has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and AKBA currently yields $0.00. In the past year, AKBA’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, AKBA has a current buyback yield of $–. This was $– for the TTM, and it was $– for the past five years.